Didcote, Lyndsay http://orcid.org/0009-0006-5516-0126
Vitoratou, Silia http://orcid.org/0000-0003-1209-8167
Al-Chalabi, Ammar http://orcid.org/0000-0002-4924-7712
Goldstein, Laura H. http://orcid.org/0000-0001-9387-3035
Funding for this research was provided by:
Motor Neurone Disease Association (Goldstein/Oct17/892-792)
Article History
Received: 28 March 2024
Accepted: 15 June 2024
First Online: 1 July 2024
Declarations
:
: This study received ethical approval from the London-Dulwich Research Ethics Committee 18/LO/1257 and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All participants gave written informed consent to participate.
: AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, Sano, Sanofi, and Wave Pharmaceuticals. AAC reports the following patent: Use of CSF-Neurofilament determinations and CSF-Neurofilament thresholds of prognostic and stratification value with regards to response to therapy in neuromuscular and neurodegenerative diseases. The other authors have no conflicts of interest to declare.